Animal-derived surfactants: Where are we? The evidence from randomized, controlled clinical trials

Journal of Perinatology

Volumn 29, Issue SUPPL. 2, 2009, Pages

  Ramanathan, R ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERACTANT; CALFACTANT; CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUCINACTANT; PALMITIC ACID; PHOSPHOLIPID; PLACEBO; PLASMALOGEN; PORACTANT; PUMACTANT; TRIPALMITIN;

CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG FORMULATION; EVIDENCE BASED PRACTICE; HUMAN; LUNG DYSPLASIA; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN MORTALITY; OUTCOME ASSESSMENT; PREMATURITY;

ANIMALS; BIOLOGICAL PRODUCTS; EVIDENCE-BASED MEDICINE; HUMANS; INFANT, NEWBORN; INTENSIVE CARE, NEONATAL; PHOSPHOLIPIDS; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SURVIVAL RATE; TREATMENT OUTCOME; VENTILATOR WEANING;

EID: 65549142330     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2009.31     Document Type: Conference Paper

References (33)

1. Martin JA, Kung HC, Mathews TJ, Hoyert DL, Strobino DM, Guyer B et al Annual summary of vital statistics: 2006. Pediatrics 2008; 121(4): 788-801.
2. Slattery MM, Morrison JJ. Preterm delivery. Lancet 2002; 360 1489-1497.
3. Tolle A, Meier W, Rudiger M, Hofmann KP, Rustow B. Effect of cholesterol and surfactant protein B on the viscosity of phospholipid mixtures. Chem Phys Lipids 2002; 114: 159-168.
4. Tolle A, Meier W, Greune G, Rudiger M, Hofmann KP, Rustow B. Plasmalogens reduce the viscosity of surfactant-like phospholipid monolayer. Chem Phys Lipids 1999; 100: 81-87.
5. Horbar JD, Wright LL, Soll RF, Wright EC, Fanaroff AA, Korones SB et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1993; 123: 757-766.
6. Alvarado M, Hingre R, Hakason D, Gross S. Clinical trial of Survanta versus Exosurf in infants <1500 g with respiratory distress syndrome. Pediatr Res 1993; 33: 314A.
7. Pearlman SA, Leef KH, Stefano JL, Speer ML, Esterly KL. A randomized trial comparing Exosurf versus Survanta in the treatment of neonatal RDS. Pediatr Res 1993; 33: 340A.
8. Sehgal SS, Ewing CK, Richards T, Taeusch HW. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study. J Natl Med Assoc 1994; 86: 46-52.
9. Vermont-Oxford Neonatal Network. A multicenter randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome Vermont-Oxford Neonatal Network. Pediatrics 1996; 97: 1-6.
10. Hudak ML, Farrell EE, Rosenberg AA, Jung AL, Auten RL, Durand DJ et al. A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome. J Pediatr 1996; 128: 396-406.
11. Hudak ML, Martin DJ, Egan EA, Matteson EJ, Cummings NJ, Jung AL et al A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics 1997; 100 39-50.
12. Modanlou HD, Beharry K, Padilla G, Norris K, Safvati S, Aranda JV. Comparative efficacy of Exosurf and Survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity. J Perinatol 1997; 17: 455-460.
13. da Costa DE, Pai MG, Al Khusaiby SM. Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: Experiences in a developing country. Pediatr Pulmonol 1999; 27: 312-317.
14. Rollins M, Jenkins J, Tubman R, Corkey C, Wilson D. Comparison of clinical responses to natural and synthetic surfactants. J Perinat Med 1993; 21: 341-347.
15. Kukkonen AK, Virtanen M, Jarvenpaa AL, Pokela ML, Ikonen S, Fellman V. Randomized trial comparing natural and synthetic surfactant: Increased infection rate after natural surfactant? Acta Paediatr 2000; 89 556-561.
16. Ainsworth SB, Beresford MW, Milligan DW, Shawn NJ, Matthews JN, Fenton AC et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: A randomised trial. Lancet 2000; 355: 1387-1392.
17. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A et al. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 2005; 115(4): 1018-1029.
18. Sinha SK, Lacaze-Masmonteil T, Soler A, Wiswell TE, Gadzinowski J, Hajdu J et al. A multicenter, randomized, controlled trial of Lucinactant versus Poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 2005; 115 1030-1038.
19. Moya F, Sinha S, Gadzinowski J, D'Agostino R, Segal R, Guardia C et al., STAR Study Investigators. One-year follow up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: Results from 2 multicenter, randomized, controlled trials. Pediatrics 2007; 119: E1361-e1370.
20. Engle WA, The Committee on Fetus Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121: 419-432.
21. Dargaville PA, Mills JM. Surfactant therapy for meconium aspiration syndrome: Current status. Drugs 2005; 65(18): 2569-2591.
22. Taeush W, Lu K, Ramirez-Schrempp D. Improving pulmonary surfactants. Acta Pharmacol Sin 2002; 23: S11-S15.
23. Rudiger M, Tolle A, Meier W, Rustow B. Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am J Physiol Lung Cell Mol Physiol 2005; 288: L379-L383.
24. Rudiger M, von Baehr A, Haupt R, Wauer RR, Rustow B. Preterm infants with high polyunsaturated fatty acid and plasmalogen content in tracheal aspirates develop bronchopulmonary dysplasia less often. Crit Care Med 2000; 28: 1572-1577.
25. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR et al Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997; 100: 31-38.
26. Bloom BT, Clark RH. Comparison of Infasurf (calfactant) and Survanta (beractant) in the prevention and treatment of respiratory distress syndrome. Pediatrics 2005; 116: 392-399.
27. Speer CP, Gefeller O, Groneck P, Laufkötter E, Roll C, Hanssler L et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child 1995; 72: F8-F13.
28. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr 2003; 162: 476-480.
29. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 2004; 21 109-119.
30. Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr 2005; 94: 779-784.
31. Clark RH, Auten RL, Peabody J. A comparison of the outcomes of neonates treated with two different natural surfactants. J Pediatr 2001; 139: 828-831.
32. Ramanathan R, Saunders WB, Lavin PT, Sekar KC, Ernst FR, Bhatia J. Mortality differences among preterm neonates treated with three different natural surfactants: Analyses from a large national database. Acta Pediatr 2007; 96(Suppl 456): 107.
33. Halliday HL. History of surfactant from 1980. Biol Neonate 2005; 87: 317-322.